novonordisk
Novo Nordisk, the Danish drug maker of the wildly successful obesity drugs, Wegovy and Ozempic, said it plans to invest $4.1 billion for a new plant in the United States to increase the manufacturing capacity of its high demand drugs. The new plant will be in Clayton, North Carolina, where the company plans to produce current and future injectable treatments for people with obesity and other serious chronic diseases. These mainly include weight loss drug Wegovy and diabetes treatment Ozempic, among others. As per reports, demand for Wegovy and Ozempic have grown significantly over supply in th...
DPA
Profit increased in the first quarter for Danish pharmaceutical company Novo Nordisk compared to the previous year. First-quarter net profit increased by 28% to 25.41 billion Danish kroner ($3 billion), the company reported. Earnings per share increased by 29% to 5.68 kroner. Operating profit increased by 27% in kroner and by 30% at constant exchange rates (CER) to 31.8 billion kroner. First quarter sales increased by 22% measured in kroner and by 24% at CER to 65.35 billion kroner in the first three months of 2024. For 2024, the company now expects operating profit growth to be 22% to 30% at ...
DPA
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら